https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47636 Tue 24 Jan 2023 14:30:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54571 Tue 14 May 2024 14:15:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41570 Thu 02 May 2024 15:43:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41043 p=.001), use of inhaled corticosteroids (68.2% and RR 2.17, 95% CI 1.19-3.99, p=.001) and short-acting β-agonists in the last 12 months (95.2% and RR 1.49, 95% CI 1.17-1.89, p=.001), as compared to those with RV negative bronchiolitis and no maternal asthma history. More children in this group had an abnormal airway resistance (33.3% and adjusted risk ratio [aRR] 3.11, 95% CI 1.03-9.47, p=.045) and reactance (27.8% and aRR 2.11, 95% CI 1.06-4.26, p=.035) at 5 Hz, as compared to those with RV negative bronchiolitis and no maternal asthma history. Conclusion: Hospitalization for RV positive bronchiolitis in early life combined with a history of maternal asthma identifies a subgroup of children with a high asthma burden while participants with only one of the two risk factors had intermediate risk for asthma.]]> Mon 08 Aug 2022 14:50:18 AEST ]]>